Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) shares shot up 5.2% on Thursday . The company traded as high as $17.83 and last traded at $17.91. 127,940 shares changed hands during trading, a decline of 77% from the average session volume of 548,511 shares. The stock had previously closed at $17.02.
Wall Street Analyst Weigh In
Several analysts have commented on the stock. Wolfe Research assumed coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price for the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Wedbush restated an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Spyre Therapeutics currently has an average rating of "Buy" and an average target price of $50.33.
Read Our Latest Analysis on Spyre Therapeutics
Spyre Therapeutics Stock Performance
The company has a market cap of $972.55 million, a P/E ratio of -2.16 and a beta of 2.98. The business's 50-day moving average price is $20.54 and its 200 day moving average price is $25.55.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.08. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.
Institutional Trading of Spyre Therapeutics
A number of hedge funds have recently modified their holdings of SYRE. GF Fund Management CO. LTD. bought a new position in Spyre Therapeutics in the 4th quarter valued at about $29,000. Huntington National Bank bought a new position in shares of Spyre Therapeutics during the fourth quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Spyre Therapeutics during the 4th quarter worth approximately $46,000. KLP Kapitalforvaltning AS bought a new stake in Spyre Therapeutics in the 4th quarter valued at $182,000. Finally, Intech Investment Management LLC acquired a new position in Spyre Therapeutics in the 3rd quarter valued at $246,000. Institutional investors and hedge funds own 80.39% of the company's stock.
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Recommended Stories
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
